Compare Gilead Sciences, Inc. (GILD) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs KLA Corp. — how do they compare? Gilead Sciences, Inc. trades at $135.56 (market cap $163.51B), while KLA Corp. trades at $219.34 (market cap $293.26B). The key difference: KLA Corp. is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | KLAC | |
|---|---|---|
Market Cap | $163.51B | $293.26B |
Sector | Health | Technology |
52-Week High | $155.80 | $301.71 |
52-Week Low | $108.22 | $84.39 |
Enterprise Value | $178.05B | $294.45B |
Dividend Yield | 2.49% | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
KLA Corporation (KLAC) trades at $219.92, down 4.54% on the day, with technical indicators showing a neutral to bearish short-term bias. The stock exhibits strong fundamentals, including a 35.66% net income margin and consistent earnings beats, most recently in Q1 2026. Revenue grew to $12.16 billion in 2025, and a 1:10 stock split is scheduled for June 12, 2026. Analyst sentiment remains largely positive, with a consensus price target of $242.33 implying potential upside.
The outlook for KLAC is supported by its dominant position in semiconductor process control and AI-driven demand, though high valuation multiples (P/E of 63.58) pose a risk. Investors face exposure to semiconductor cycle volatility and competitive pressures, but the company's profitability and analyst bullishness suggest long-term growth potential if execution remains strong.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
